DXCM DEXCOM INC.

DexCom Opens Data Platform and Launches Developer Program to Fuel Diabetes App Innovation

DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (CGM), announced today the availability of a public API, empowering third-party developers to connect patient-authorized CGM data into a broad range of software applications. This pioneering approach to CGM data sharing is intended to enable a rich ecosystem of novel solutions and put the user in control of where and how they interact with their glucose data.

“In launching this developer platform, Dexcom combines our CGM data expertise with the creativity of the developer ecosystem to enable new solutions and business models in the treatment and management of diabetes,” said Annika Jimenez, Senior Vice President of Data, Dexcom. “Dexcom believes in data mobility and customer choice. It also believes that the API opens up opportunities to drive Dexcom CGM data into the heart of new digital solutions for payers, providers, and most importantly people with diabetes.”

Continuous glucose monitoring allows people with diabetes to continuously track their blood glucose levels in real-time. Dexcom CGM systems provide dynamic glucose information every five minutes, which creates a continuous stream of glucose data that can be invaluable for individual and population diabetes management. The Dexcom API allows Dexcom to ensure CGM data collaboration is secure, patient-privacy-centric, and FDA-compliant, while supporting a broad variety of new solutions and business models.

"Diabetes is a data-driven disease," said Jeff Dachis, Founder and Chief Executive Officer of One Drop, a leading digital diabetes management solution and Dexcom API user. “By combining Dexcom data with One Drop’s ability to connect users, coaches and diabetes peers, this partnership will help drive innovation and will bring about more affordable, accessible, scalable, and effective solutions. It's a big win for people with diabetes.”

As of today, developers in the US can register at https://developer.dexcom.com and immediately access the Dexcom API. Several well-established companies and startups in the diabetes space including One Drop, Nutrino, Tidepool, Rimidi, Evidation, Ensa, and App Practice are already accessing the API for patient-approved CGM data retrieval.

“AppPractice’s new platform allows clinicians to view their patient’s glucose on the same day via their smartphones, as part of their mHealth patient care practice,” said Dr. Rakesh Patel, Endocrinologist, entrepreneur and founder of App Practice. “By using the data from the Dexcom API, our clinicians can now make timely changes and adjust insulin for their patients more effectively. Access to patient data like this enables clinicians to dramatically improve patient care and can lower healthcare costs.”

Dexcom customers will benefit from the apps these companies have developed in many ways; for example:

  • Clinicians can now view their diabetes patients’ glucose data on their smartphones, as part of their mobile practice patient care and billing workflows.
  • Patients are able to receive automated, personalized insights gained from combining data from their diabetes devices, medical records, and other apps and wearables.
  • Dexcom users can explore how their food choices impact their glucose control and connect with and learn from coaches and diabetes peers in a data-driven community.

“Dexcom has always been a pioneer in diabetes technology,” said Kevin Sayer, President and CEO, Dexcom. “Now we are extending our thought leadership into the data our device generates by enabling broad collaboration with digital health partners.”

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com.

EN
19/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Dexcom Inc: 2 directors

Two Directors at Dexcom Inc sold/bought 22,148 shares at between 55.039USD and 55.170USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

OSK OSHKOSH CORP
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch